This is a Phase 1b/2, multi-center, open label umbrella study of patients ≥12 years of age with recurrent, progressive, or refractory melanoma or other solid tumors with alterations in the key protein

NIAID Data Ecosystem20

Clinical Activity, Safety and Immunogenic Properties of Cancer Immunotherapeutic GSK2132231A in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma

癌症免疫治疗

黑色素瘤临床试验

The clinical objective of this clinical trial is to examine the clinical activity in terms of tumor response and time to treatment failure of the immunotherapeutic product GSK2132231A when given to pa

DataCite Commons2025-06-01 更新20

Phase II trial melphalan ILI plus ADH-1 for treatment of in-transit extremity melanoma

黑色素瘤临床试验

化疗反应基因表达谱

An evaluation of biopsies from patients with in-transit extremity melanoma who have been treated with ADH-1 followed by melphalan in the setting of isolated limb infusion Gene expression profiles were

NIAID Data Ecosystem20

Phase II trial melphalan ILI plus ADH-1 for treatment of in-transit extremity melanoma

资源简介：

相关数据集